Supplementary Figure 1 from Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial
Maggie C.U. Cheang(Institute of Cancer Research), Torsten O. Nielsen(University of British Columbia), Philip S. Bernard(University of Utah), Samuel Leung(BC Cancer Agency), Inge J. Stijleman, Matthew J. Ellis(University of California, Davis), Kathleen I. Pritchard, Joel S. Parker(University of North Carolina at Chapel Hill), Mark Ebbert(University of Kentucky), Charles M. Perou(University of North Carolina at Chapel Hill), Dongsheng Tu(Ontario Institute for Cancer Research), Sherri R. Davies(Washington University in St. Louis), Stephen Chia(BC Cancer Agency), Shan Jiang(The Affiliated Yongchuan Hospital of Chongqing Medical University), Mark Levine(Emory University), Lois E. Shepherd(Ontario Institute for Cancer Research), Carole Davis(Unknown), K. David Voduc(BC Cancer Agency)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k